[1] SUNG H, FERLAY J, SIEGEL R L, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
[2] VILLANUEVA A.Hepatocellular Carcinoma[J]. N Engl J Med, 2019, 380(15):1450-1462.
[3] EASL Clinical Practice Guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1):182-236.
[4] HSU C Y, LIU P H, HO S Y, et al.Metastasis in patients with hepatocellular carcinoma: prevalence, determinants, prognostic impact and ability to improve the Barcelona Clinic Liver Cancer system[J]. Liver Int, 2018, 38(10):1803-1811.
[5] Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma[J]. Cell, 2017, 169(7):1327-1341.e1323.
[6] GAO Q, ZHU H, DONG L, et al. Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma[J]. Cell, 2019, 179(2):561-577.e522.
[7] GANESH K, MASSAGUé J.Targeting metastatic cancer[J]. Nat Med, 2021, 27(1):34-44.
[8] BIRKBAK N J, MCGRANAHAN N.Cancer Genome Evolutionary Trajectories in Metastasis[J]. Cancer Cell, 2020, 37(1):8-19.
[9] VAN DER AUWERA G A, CARNEIRO M O, HARTL C, et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline[J]. Curr Protoc Bioinformatics, 2013, 43(1110):11.10.11-11.10.33.
[10] REBOUISSOU S, NAULT J C.Advances in molecular classification and precision oncology in hepatocellular carcinoma[J]. J Hepatol, 2020, 72(2):215-229.
[11] LETOUZé E, SHINDE J, RENAULT V, et al.Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis[J]. Nat Commun, 2017, 8(1):1315.
[12] LAWRENCE M S, STOJANOV P, POLAK P, et al.Mutational heterogeneity in cancer and the search for new cancer-associated genes[J]. Nature, 2013, 499(7457):214-218.
[13] TURAJLIC S, SWANTON C.Metastasis as an evolutionary process[J]. Science, 2016, 352(6282):169-175.
[14] FAVERO F, JOSHI T, MARQUARD A M, et al.Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data[J]. Ann Oncol, 2015, 26(1):64-70.
[15] MERMEL C H, SCHUMACHER S E, HILL B, et al.GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers[J]. Genome Biol, 2011, 12(4):R41.
[16] REITER J G, MAKOHON-MOORE A P, GEROLD J M, et al. Reconstructing metastatic seeding patterns of human cancers[J]. Nat Commun, 2017, 8:14114.
[17] WU P, HOU L, ZHANG Y, et al.Phylogenetic tree inference: a top-down approach to track tumor evolution[J]. Front Genet, 2019, 10:1371.
[18] XIE D Y, FAN H K, REN Z G, et al.Identifying clonal origin of multifocal hepatocellular carcinoma and its clinical implications[J]. Clin Transl Gastroenterol, 2019, 10(2):e00006.
[19] FURUTA M, UENO M, FUJIMOTO A, et al.Whole genome sequencing discriminates hepatocellular carcinoma with intrahepatic metastasis from multi-centric tumors[J]. J Hepatol, 2017, 66(2):363-373.
[20] ZHOU S L, ZHOU Z J, SONG C L, et al.Whole-genome sequencing reveals the evolutionary trajectory of HBV-related hepatocellular carcinoma early recurrence[J]. Signal Transduct Target Ther, 2022, 7(1):24.
[21] YANG S L, LUO Y Y, CHEN M, et al.A systematic review and meta-analysis comparing the prognosis of multicentric occurrence and vs. intrahepatic metastasis in patients with recurrent hepatocellular carcinoma after hepatectomy[J]. HPB (Oxford), 2017, 19(10):835-842.
[22] GUNDEM G, VAN LOO P, KREMEYER B, et al.The evolutionary history of lethal metastatic prostate cancer[J]. Nature, 2015, 520(7547):353-357.
[23] BROWN D, SMEETS D, SZéKELY B, et al. Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations[J]. Nat Commun, 2017, 8:14944.
[24] CONNOR A A, DENROCHE R E, JANG G H, et al. Integration of genomic and transcriptional features in pancreatic cancer reveals increased cell cycle progression in metastases[J]. Cancer Cell, 2019, 35(2):267-282.e267.
[25] KLEIN C A.Parallel progression of primary tumours and metastases[J]. Nat Rev Cancer, 2009, 9(4):302-312.
[26] HU Z, DING J, MA Z, et al.Quantitative evidence for early metastatic seeding in colorectal cancer[J]. Nat Genet, 2019, 51(7):1113-1122.
[27] HU Z, LI Z, MA Z, et al.Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases[J]. Nat Genet, 2020, 52(7):701-708.
[28] HOSSEINI H, OBRADOVIĆ M M S, HOFFMANN M, et al. Early dissemination seeds metastasis in breast cancer[J]. Nature, 2016, 540(7634):552-558.
[29] GRIFFITH M, SPIES N C, KRYSIAK K, et al.CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer[J]. Nat Genet, 2017, 49(2):170-174.
[30] FRESHOUR S L, KIWALA S, COTTO K C, et al.Integration of the Drug-Gene Interaction Database (DGIdb 4.0) with open crowdsource efforts[J]. Nucleic Acids Res, 2021, 49(D1):D1144-d1151.
[31] WISHART D S, FEUNANG Y D, GUO A C, et al.DrugBank 5.0: a major update to the DrugBank database for 2018[J]. Nucleic Acids Res, 2018, 46(D1):D1074-d1082.
[32] LLOVET J M, VILLANUEVA A, LACHENMAYER A, et al.Advances in targeted therapies for hepatocellular carcinoma in the genomic era[J]. Nat Rev Clin Oncol, 2015, 12(7):408-424.
[33] YU G, XU S, HACKL T. Aplot: Decorate a ‘ggplot’ with Associated Information[EB/OL]. (2023-10-06)[2024-01-08]. https://CRAN.R-project.org/package=aplot.
[34] SWANTON C.Intratumor heterogeneity: evolution through space and time[J]. Cancer Res, 2012, 72(19):4875-4882.
[35] NGUYEN B, FONG C, LUTHRA A, et al. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients[J]. Cell, 2022, 185(3):563-575.e511.
[36] NGUYEN P H D, MA S, PHUA C Z J, et al. Intratumoural immune heterogeneity as a hallmark of tumour evolution and progression in hepatocellular carcinoma[J]. Nat Commun, 2021, 12(1):227.
[37] ROONEY M S, SHUKLA S A, WU C J, et al.Molecular and genetic properties of tumors associated with local immune cytolytic activity[J]. Cell, 2015, 160(1-2):48-61.
[38] ROBINSON D R, WU Y M, LONIGRO R J, et al.Integrative clinical genomics of metastatic cancer[J]. Nature, 2017, 548(7667):297-303.
[39] WATKINS T B K, LIM E L, PETKOVIC M, et al. Pervasive chromosomal instability and karyotype order in tumour evolution[J]. Nature, 2020, 587(7832):126-132.
[40] TURAJLIC S, XU H, LITCHFIELD K, et al. Tracking cancer evolution Reveals constrained routes to metastases: TRACERx renal[J]. Cell, 2018, 173(3):581-594.e512.
[41] YOSHIHARA K, SHAHMORADGOLI M, MARTíNEZ E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data[J]. Nat Commun, 2013, 4:2612.
[42] SUN Y, WU L, ZHONG Y, et al. Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma[J]. Cell, 2021, 184(2):404-421.e416.
[43] TIAN J, TANG Z Y, YE S L, et al.New human hepatocellular carcinoma (HCC) cell line with highly metastatic potential (MHCC97) and its expressions of the factors associated with metastasis[J]. Br J Cancer, 1999, 81(5):814-821.
[44] QIU Z, LI H, ZHANG Z, et al. A Pharmacogenomic Landscape in Human Liver Cancers[J]. Cancer Cell, 2019, 36(2):179-193.e111.
[45] SUN Y F, XU Y, YANG X R, et al.Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection[J]. Hepatology, 2013, 57(4):1458-1468.
[46] JIN S, GUERRERO-JUAREZ C F, ZHANG L, et al. Inference and analysis of cell-cell communication using CellChat[J]. Nat Commun, 2021, 12(1):1088. |
